ifosfamide has been researched along with ramosetron in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujita, A; Hayakawa, T; Hirohata, T; Inotsume, N; Konaka, M; Makino, A; Sato, H; Sato, M; Sekine, K; Totsu, S; Wada, Y | 1 |
| Hashimoto, R; Ikeda, K; Kurokawa, N; Okamoto, Y; Takagi, T; Takenaka, M; Ueda, T; Uejima, E | 1 |
2 other study(ies) available for ifosfamide and ramosetron
| Article | Year |
|---|---|
[Comparison of ramosetron and azasetron for prevention of acute and delayed cisplatin-induced emesis in lung cancer patients].
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Camptothecin; Cisplatin; Female; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Oxazines; Retrospective Studies; Vomiting, Anticipatory | 2006 |
[Comparison of antiemetic efficacy of 5-HT3 receptor antagonists in orthopedics cancer patients receiving high-dose chemotherapy].
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bone Neoplasms; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Granisetron; Humans; Ifosfamide; Male; Middle Aged; Nausea; Ondansetron; Osteosarcoma; Prospective Studies; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2007 |